New drug LM-350 takes on advanced tumors in first human trial

NCT ID NCT07112222

Recruiting now Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 31 times

Summary

This study tests an experimental drug called LM-350 in about 80 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has two parts: first to check safety and dosing, then to measure anti-tumor effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China

Contact
Cancer Care Wollongong Pty Limited
RECRUITING

Wollongong, New South Wales, Australia

Contact
Cancer Research SA
RECRUITING

Adelaide, South Australia, Australia

Contact
Peninsula and South Eastern Haematology and Oncology Group
RECRUITING

Frankston, Victoria, Australia

Contact

Conditions

Explore the condition pages connected to this study.

MALIGNANT TUMORS MALIGNANT TUMORS